29P - Human papillomavirus and non small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Thoracic Malignancies
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Kostantinos Syrigos
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors K. Syrigos1, T. Raptakis2, A. Koumarianou3, D. Grapsa1, A. Ntokou1, A. Nikolaou1, V. Skouras4, P. Karakitsos5
  • 1Oncology Unit, 3rd Department Of Medicine, University of Athens, “Sotiria” General Chest Diseases Hospital, 11527 - Athens/GR
  • 22nd Department Of Pulmonology, Attikon University Hospital, 12462 - Athens/GR
  • 3Fourth Department Of Internal Medicine,, Attikon University Hospital, 12462 - Athens/GR
  • 4Department Of Pulmonology, 401 Army General Hospital, Athens/GR
  • 5Pathology Department, Attikon University Hospital, 12462 - Athens/GR



Human Papilloma Virus (HPV) belongs to a highly heterogeneous family of epithelio-tropic, encapsulated DNA viruses with established causative role in cervical and oropharyngeal cancer. The association of HPV infection in the development of lung cancer, the most common cause of death from cancer worldwide, has not been clarified, as several studies on the issue came up with contradictory results. In this study we addressed the relationship of HPV and Non Small Cell Lung Cancer (NSCLC) in consecutive patients undergoing bronchoscopy in our department.


Study Design – this is a non-interventional, case-control study that was conducted at “ATTIKON” University General Hospital, Athens, Greece. Consecutive patients referred for bronchoscopy were enrolled and depending on the indication of bronchoscopy, were allocated to two groups: the study group that was comprised of patients suspected of lung cancer and with a final diagnosis of NSCLC, and the control group with patients undergoing bronchoscopy for other indications. All patients had undergone standard pre-bronchoscopic evaluation. Patients under 18 years old, with a contraindication for bronchoscopy and patients who refused or were unable to provide informed consent, were excluded. A detailed medical history with emphasis on HPV-related diseases and demographics were recorded. Cytology specimens (bronchial brushing or bronchoalveolar lavage) were tested for 35 different HPV genotypes; flow cytometric E6/E7 HPV oncoprotein mRNA detection was also conducted to further determine the transcriptional status of the virus.


Among the ‘lung malignancy’ twenty seven patients, twenty had a final diagnosis of NSCLC, comprising the study group, six had a diagnosis of Small Cell Lung Cancer (SCLC) and one patient suffered from metastatic colon cancer. Non-cancer controls suffered from a variety of pulmonary diseases. No HPV DNA or E6/E7 HPV mRNA was detected in any cytology specimen of study participants, in both the study and the control group.


No evidence of HPV association in lung carcinogenesis was derived from this study. Our results do not support a causal role for HPV infection in the development of lung cancer.

Clinical trial identification

Legal entity responsible for the study

University of Athens


University of Athens


All authors have declared no conflicts of interest.